C 
Chugai Pharmaceutical Co 4519.T · JPY
Health Care · Pharmaceuticals · Tokyo Stock Exchange · 🇯🇵 Japan
6,806
-5.34%
Close of 6 Nov 2026, in JPY
At a glance
Figures in JPY, from our data supplier.
Revenue
¥1.26trn
FY2016FY2025
Net income
¥434.01bn
FY2016FY2025
Free cash flow
¥313.18bn
FY2016FY2025
Shareholders' equity
¥2.03trn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ¥1.26trn | ¥1.17trn | ¥1.11trn | ¥1.26trn | ¥999.76bn | ¥786.95bn | ¥686.18bn | ¥579.79bn | ¥534.20bn | ¥491.78bn |
| Gross profit | ¥894.25bn | ¥830.75bn | ¥693.01bn | ¥783.06bn | ¥660.27bn | ¥511.77bn | ¥419.92bn | ¥316.02bn | ¥279.57bn | ¥243.55bn |
| Research and development | ¥187.60bn | ¥176.74bn | ¥164.76bn | ¥148.36bn | ¥131.28bn | ¥116.60bn | ¥104.73bn | ¥93.93bn | ¥88.82bn | ¥82.53bn |
| Operating income | ¥591.22bn | ¥543.91bn | ¥415.67bn | ¥533.94bn | ¥433.74bn | ¥306.88bn | ¥214.51bn | ¥129.22bn | ¥97.09bn | ¥79.32bn |
| Net income | ¥434.01bn | ¥387.32bn | ¥325.47bn | ¥374.43bn | ¥303.00bn | ¥214.73bn | ¥157.56bn | ¥92.49bn | ¥72.71bn | ¥53.59bn |
| Diluted earnings per share | 263.72 | 235.27 | 197.79 | 227.57 | 184.16 | 130.75 | 95.99 | 56.35 | 44.34 | 32.72 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | ¥2.47trn | ¥2.21trn | ¥1.93trn | ¥1.87trn | ¥1.54trn | ¥1.24trn | ¥1.06trn | ¥919.55bn | ¥852.47bn | ¥806.28bn |
| Cash and short-term investments | ¥979.70bn | ¥996.35bn | ¥738.98bn | ¥503.11bn | ¥471.97bn | ¥378.62bn | ¥333.06bn | ¥249.39bn | ¥243.09bn | ¥205.54bn |
| Total liabilities | ¥442.86bn | ¥306.87bn | ¥306.97bn | ¥445.37bn | ¥350.68bn | ¥255.50bn | ¥204.93bn | ¥163.02bn | ¥159.58bn | ¥159.79bn |
| Debt | — | ¥10.90bn | ¥13.46bn | ¥14.11bn | ¥16.04bn | ¥11.28bn | ¥12.75bn | ¥215.0m | ¥336.0m | ¥645.0m |
| Shareholders' equity | ¥2.03trn | ¥1.90trn | ¥1.63trn | ¥1.42trn | ¥1.19trn | ¥980.00bn | ¥853.99bn | ¥755.86bn | ¥691.92bn | ¥645.51bn |
| Shares outstanding | 1,646m | 1,646m | 1,646m | 1,645m | 1,645m | 1,642m | 1,641m | 1,641m | 1,640m | 1,638m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | ¥389.45bn | ¥447.60bn | ¥409.93bn | ¥244.11bn | ¥279.63bn | ¥205.03bn | ¥206.64bn | ¥119.07bn | ¥107.62bn | ¥38.79bn |
| Capital spending | −¥76.27bn | −¥50.92bn | −¥74.26bn | −¥71.24bn | −¥72.87bn | −¥61.41bn | −¥61.18bn | −¥77.67bn | −¥44.53bn | −¥36.42bn |
| Free cash flow | ¥313.18bn | ¥396.68bn | ¥335.67bn | ¥172.87bn | ¥206.76bn | ¥143.62bn | ¥145.46bn | ¥41.40bn | ¥63.10bn | ¥2.37bn |
| Dividends paid | −¥299.42bn | −¥133.25bn | −¥131.59bn | −¥138.22bn | −¥98.64bn | −¥91.44bn | −¥56.37bn | −¥35.01bn | −¥30.05bn | −¥31.68bn |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ¥341.58bn | ¥321.75bn | ¥346.30bn | ¥333.18bn | ¥290.00bn | ¥288.46bn | ¥302.07bn | ¥315.68bn |
| Gross profit | ¥237.97bn | ¥228.96bn | ¥258.74bn | ¥232.94bn | ¥201.94bn | ¥200.64bn | ¥207.77bn | ¥231.46bn |
| Operating income | ¥160.57bn | ¥162.67bn | ¥131.91bn | ¥179.15bn | ¥140.26bn | ¥138.87bn | ¥123.13bn | ¥160.66bn |
| Net income | ¥116.33bn | ¥115.42bn | ¥128.41bn | ¥111.21bn | ¥97.16bn | ¥97.23bn | ¥91.60bn | ¥109.50bn |
| Diluted earnings per share | 70.69 | 70.14 | 78.03 | 67.58 | 59.03 | 59.08 | 55.64 | 66.51 |
| Cash from operations | ¥128.05bn | ¥123.40bn | ¥130.04bn | ¥72.07bn | ¥120.00bn | ¥67.34bn | ¥152.39bn | ¥124.37bn |
| Capital spending | −¥8.59bn | −¥12.70bn | −¥17.37bn | −¥9.98bn | −¥26.82bn | −¥22.10bn | −¥316.0m | −¥17.52bn |
| Free cash flow | ¥119.46bn | ¥110.71bn | ¥112.67bn | ¥62.09bn | ¥93.17bn | ¥45.24bn | ¥152.08bn | ¥106.85bn |
| Total assets | ¥2.45trn | ¥2.27trn | ¥2.47trn | ¥2.18trn | ¥2.28trn | ¥2.14trn | ¥2.21trn | ¥2.07trn |
| Cash and short-term investments | ¥962.57bn | ¥850.10bn | ¥979.70bn | ¥882.45bn | ¥1.03trn | ¥944.55bn | ¥996.35bn | ¥845.32bn |
| Debt | — | — | — | — | — | — | ¥6.37bn | — |
| Shareholders' equity | ¥2.03trn | ¥1.91trn | ¥2.03trn | ¥1.89trn | ¥1.99trn | ¥1.91trn | ¥1.90trn | ¥1.80trn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | -0.1% | 9.8% | 9.7% |
| Operating income | 3.5% | 14.0% | 20.9% |
| Net income | 5.0% | 15.1% | 21.7% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 71.0% | 66.7% | 66.4% | 62.8% |
| Operating margin | 46.7% | 43.4% | 42.9% | 36.6% |
| Net margin | 33.8% | 31.7% | 31.0% | 26.4% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 31.3 | 29.8 | 27.0 | 14.8 | 20.3 | 42.1 | 35.0 | 37.7 | 43.4 | 34.2 |
| Price to sales | 10.8 | 9.8 | 7.9 | 4.4 | 6.2 | 11.5 | 8.0 | 6.0 | 5.9 | 3.7 |
Dividends and splits
Per share, in the currency the company pays
Paid for 37 years. Last went ex-dividend on 29 Jun 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 141.00 | 132.00 | 81.00 | 80.00 | 84.00 | 60.00 | 55.667 | 20.667 |
- 3-for-1 split · 29 Jun 2020
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.